- Roth Capital analyst Philip Shen upgraded Array Technologies Inc (NASDAQ:ARRY) to Buy from Neutral with a $25 price target, implying an upside of 82.3%.
- Shen is incrementally more bullish ahead of the company’s Q2 report due on Aug. 11.
- With shares down about 45% since the company’s Q1 report, he sees the potential for the stock to leap higher on any healthy amount of good news such as reinstating guidance.
- Shen’s checks suggest Array may now be in a better financial position and could even gain share through the challenges posed by steel pricing.
- Array has a Q2 revenue consensus of $233.2 million and an EPS consensus of $0.03.
- Price Action: ARRY shares traded higher by 4.96% at $14.39 in the premarket session on the last check Tuesday.
Vera Therapeutics Highlights Presentation Of Phase 2a Data Showing Atacicept Reduces Serum Gd-IgA1 In Patients With Nephropathy At American Society Of Nephrology Kidney Week
Phase 2a JANUS clinical trial showed atacicept administered subcutaneously once weekly demonstrated a durable and substantial reduction in serum galactose-deficient IgA1 (Gd-IgA1) in a dose-dependent manner up to 72
